The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ruby Qc Investment Holdings Pte Ltd
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Microcap 250 and 0.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ruby QC Investment Holdings Pte Ltd, a Singapore-based investor and not part of the promoter/promoter group, has sold its entire equity stake of 72,78,535 shares (4.6244% of Akums Drugs' share capital) through a Block Deal on December 22, 2025. Before this transaction, Ruby QC held exactly these 72,78,535 shares (4.6244%); after the disposal, its holding has fallen to zero, meaning a complete exit from the company. The transaction was executed on the NSE/BSE at face value Rs 2 per share reporting basis. Because the seller is a foreign (Singapore) entity, this represents a full FII exit from Akums Drugs. The disclosure is mandatory under SEBI's takeover regulations since the stake crossed the 5% reporting threshold threshold logic for disposals.
This is a significant foreign institutional investor exit — a Singapore-based fund has fully sold off its 4.62% stake via a block deal, which could create short-term supply pressure on the stock but also signals a clean change of hands. Retail investors should monitor post-block-deal price action and check whether any new large holder has accumulated this stake.